JP2019525894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019525894A5 JP2019525894A5 JP2018563622A JP2018563622A JP2019525894A5 JP 2019525894 A5 JP2019525894 A5 JP 2019525894A5 JP 2018563622 A JP2018563622 A JP 2018563622A JP 2018563622 A JP2018563622 A JP 2018563622A JP 2019525894 A5 JP2019525894 A5 JP 2019525894A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- hydroxyl
- vitamin
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 72
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 51
- 229930003316 Vitamin D Natural products 0.000 claims description 43
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 43
- 235000019166 vitamin D Nutrition 0.000 claims description 43
- 239000011710 vitamin D Substances 0.000 claims description 43
- -1 vitamin D compound Chemical class 0.000 claims description 43
- 229940046008 vitamin d Drugs 0.000 claims description 43
- 150000002367 halogens Chemical group 0.000 claims description 39
- 229910052736 halogen Inorganic materials 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 239000001257 hydrogen Substances 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 150000002431 hydrogen Chemical class 0.000 claims description 30
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- 238000002512 chemotherapy Methods 0.000 claims description 24
- 229960005084 calcitriol Drugs 0.000 claims description 18
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 239000011612 calcitriol Substances 0.000 claims description 12
- 235000020964 calcitriol Nutrition 0.000 claims description 12
- 208000022605 chemotherapy-induced alopecia Diseases 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 230000000977 initiatory effect Effects 0.000 claims description 8
- 210000004761 scalp Anatomy 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- BJYLYJCXYAMOFT-RRXOBRNQSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCC(O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RRXOBRNQSA-N 0.000 claims description 6
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000004665 trialkylsilyl group Chemical group 0.000 claims description 6
- 239000011647 vitamin D3 Substances 0.000 claims description 6
- 229940021056 vitamin d3 Drugs 0.000 claims description 6
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 210000003780 hair follicle Anatomy 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 201000001342 Fallopian tube cancer Diseases 0.000 claims description 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims description 2
- 206010038111 Recurrent cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 210000000981 epithelium Anatomy 0.000 claims description 2
- 201000008815 extraosseous osteosarcoma Diseases 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims 1
- 210000004207 dermis Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 45
- 238000011200 topical administration Methods 0.000 description 13
- 201000004384 Alopecia Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 208000037147 Hypercalcaemia Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000148 hypercalcaemia Effects 0.000 description 2
- 208000030915 hypercalcemia disease Diseases 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 230000003700 hair damage Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000001184 hypocalcaemic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345857P | 2016-06-05 | 2016-06-05 | |
| US62/345,857 | 2016-06-05 | ||
| PCT/US2017/036011 WO2017214064A1 (en) | 2016-06-05 | 2017-06-05 | Preventing or mitigating chemotherapy induced alopecia using vitamin d |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019525894A JP2019525894A (ja) | 2019-09-12 |
| JP2019525894A5 true JP2019525894A5 (enExample) | 2020-07-16 |
| JP7208016B2 JP7208016B2 (ja) | 2023-01-18 |
Family
ID=60578902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563622A Active JP7208016B2 (ja) | 2016-06-05 | 2017-06-05 | ビタミンｄを使用する化学療法誘発性脱毛症の予防又は軽減 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20190343847A1 (enExample) |
| EP (1) | EP3463283A4 (enExample) |
| JP (1) | JP7208016B2 (enExample) |
| AU (1) | AU2017278257B2 (enExample) |
| CA (1) | CA3026495A1 (enExample) |
| WO (1) | WO2017214064A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010282731C1 (en) | 2009-08-14 | 2016-04-21 | Berg Llc | Vitamin D3 and analogs thereof for treating alopecia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6844326B2 (en) * | 1995-06-07 | 2005-01-18 | Anticancer, Inc. | Treatment of alopecia |
| AU2010282731C1 (en) | 2009-08-14 | 2016-04-21 | Berg Llc | Vitamin D3 and analogs thereof for treating alopecia |
| CA2913543C (en) * | 2013-05-29 | 2024-01-09 | Berg Llc | Preventing or mitigating chemotherapy induced alopecia using vitamin d |
-
2017
- 2017-06-05 US US16/307,404 patent/US20190343847A1/en not_active Abandoned
- 2017-06-05 WO PCT/US2017/036011 patent/WO2017214064A1/en not_active Ceased
- 2017-06-05 EP EP17810805.6A patent/EP3463283A4/en active Pending
- 2017-06-05 AU AU2017278257A patent/AU2017278257B2/en active Active
- 2017-06-05 CA CA3026495A patent/CA3026495A1/en active Pending
- 2017-06-05 JP JP2018563622A patent/JP7208016B2/ja active Active
-
2022
- 2022-11-04 US US17/981,038 patent/US20230302022A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12343342B2 (en) | Methods for treating soft tissue sarcoma | |
| BR112019018880A2 (pt) | composições de plinabulina e seu uso | |
| JP2016523226A5 (enExample) | ||
| JP2002542293A (ja) | 医薬組成物 | |
| JP2013501790A5 (enExample) | ||
| CN108348469A (zh) | 治疗性组合物 | |
| US20220023317A1 (en) | Preventing or mitigating chemotherapy induced alopecia using vitamin d | |
| JP2019525894A5 (enExample) | ||
| JP2016525569A (ja) | 発汗過多の治療のための局所用組成物およびその使用方法 | |
| EP1677754A1 (en) | Methods and compositions for treating erectile dysfunction | |
| WO2023081720A1 (en) | Uses of pan bet inhibitors | |
| US20230302022A1 (en) | Preventing or mitigating chemotherapy induced alopecia using vitamin d | |
| CN106794192A (zh) | 包含齐墩果酸衍生物及其药学上可接受的盐的用于防止脱发或促进毛发生长的组合物 | |
| EP3010508B1 (en) | Combination of ro5503781, capecitabine and oxaliplatin for cancer therapy | |
| KR20120035691A (ko) | 손톱 또는 발톱 성장 촉진용 조성물 | |
| EP3487501A1 (en) | Methods, compositions, and compounds for treatment of dermatological and ocular conditions | |
| EP0175644A2 (en) | New pharmaceutical use of somatostatin analogues | |
| KR101703677B1 (ko) | 사포닌 유도체 및 이의 약학적으로 허용가능한 염을 포함하는 탈모방지 또는 발모촉진용 조성물 | |
| US20180200263A1 (en) | TOPICAL TREATMENT REGIMENS CONTAINING A PROSTAGLANDIN F2a ANALOG AND A TOPICAL STEROID | |
| RU2020118559A (ru) | Составы фулвестранта и способы их применения | |
| WO2007023841A1 (ja) | 発毛剤組成物 | |
| JPH10245393A (ja) | トリテルペン類を含有する組成物 | |
| US20140364405A1 (en) | Treatment of seborrhoea | |
| HK1221416B (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
| JPS63183527A (ja) | グルココルチコイド作用増強剤 |